An interventional study of SREC in Nicotine Dependence, Tobacco Toxicity and Nicotine Dependence, Cigarettes, sponsored by University of California, San Francisco. Withdrawn at 1 site in United States. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-09.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Tobacco Use Disorder by University of California, San Francisco — 5 open to participants now, 5 under way, none of them phase 3. Tobacco Use Disorder · University of California, San Francisco.
Among the 32 studies in Tobacco Use Disorder by University of California, San Francisco, this one is the 30th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2022, is one of 21 with no phase, and was the 16th registered.
1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.
Browse Tobacco Use Disorder studies →5 of the 32 studies in Tobacco Use Disorder by University of California, San Francisco are open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 13+ · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 21–65 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.
This study: 21 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2022.
Median enrollment 108 across the 31 interventional studies, 135 across the 1 observational. Of the 25 that completed or were terminated, 6 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, San Francisco is the lead sponsor of 2,171 studies on the registry; 370 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 203 (76%) have results posted.
5 of the studies in Tobacco Use Disorder by University of California, San Francisco that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06170437University of California, San FranciscoSmoke-free Home Study in Subsidized Housing | 2026-12-31 |
| NCT07540780University of California, San FranciscoSocial Media Support Groups for Adolescent Vaping Cessation | 2027-01-31 |
| NCT05962229University of California, San FranciscoComparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine | 2027-05 |
| NCT06678672University of California, San FranciscoContingency Management for Veteran Smokers Undergoing Major Elective Surgery | 2027-06-01 |
| NCT07148232University of California, San FranciscoExtended Intervention for Tobacco Use (EXIT) for People Experiencing Homelessness | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 32 studies in Tobacco Use Disorder by University of California, San Francisco, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational, crossover study that will be examine use behaviors, chemical exposures, and biological effects of SREC compared to TC use in subjects confined to a research ward setting.
Daily cigarette smokers who are familiar with e-cigarette (EC) use will be instructed to use only NIDA Standardized Research Electronic Cigarettes (SREC) and tobacco cigarettes (TC) while enrolled on the study. Our overall goals are two-fold: (1) to compare nicotine and toxicant exposure and pharmacological effects of SREC used alone vs tobacco cigarettes alone (TC), or dual use; and (2) using SREC alone, TC alone, or ad libitum SREC use combined with 50% reduction in usual TC use as a model for dual use, to examine the extent to which nicotine and toxicant exposure and biomarkers of potential harm compare among the 3 groups. The former would inform the effects of total switching, the latter would inform the potential harm reducing effects of smoking fewer TC while using EC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; pharmacokinetic (PK) blood draws; ad libitum use of product; cardiovascular (CV) monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
Other: SREC
Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; PK blood draws; ad libitum use of product; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
Other: SREC
Four days of SREC and/or usual product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes ad libitum SREC use and less than usual amount of cigarette use; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
Other: SREC
The Standardized Research E-Cigarette (SREC) was developed by NIDA to help researchers assess uncertainties in electronic nicotine delivery devices. Tank: * Sealed and disposable * Minimum 350 puffs per tank * Volume of e-liquid per tank \~ 3ml E-Liquid Characteristics: * Tobacco flavored * Nicotine concentration: 15 mg/ml * Propylene Glycol:\~ 50% (wt / wt) * Glycerin: \~ 50% (wt / wt) * Cotinine: \<1 μg/g * Nornicotine: 5 μg/g * Myosmine : 3 μg/g * Anabasine: \<1 μg/g * Anatabine: \<1 μg/g * Beta:nicotyrine: \<1 μg/g * Diacetyl: \<2 μg/g * 2,3:Pentanedione: \<1 μg/g * Arsenic: \<0.1 μg/g * Cadmium: \<0.1 μg/g * Chromium: \<0.1 μg/g * Lead: \<0.1 μg/g * Nickel: \<0.1 μg/g * Mercury: \<0.05 μg/g
Also known as: Standardized Research E-Cigarette
Peak Nicotine Concentration
Compare peak nicotine concentration between SREC vs. Tobacco Cigarette (TC) use
Time frame: Up to 2 years
Time of Peak Nicotine Concentration
Compare time of peak nicotine concentration between SREC vs. Tobacco Cigarette (TC) use
Time frame: Up to 2 years
Mean overall systemic nicotine exposure
Descriptive statistics will be used to examine systemic nicotine exposure from daily use of SREC and compare daily nicotine intake to TC use
Time frame: Baseline through study completion, approximately 2 years
Change in Mean score on the Modified Cigarette Evaluation Questionnaire (mCEQ)
The mCEQ use three multi-item domains (subscales) and two single items: "Smoking Satisfaction", "Psychological Reward", "Aversion", "Enjoyment of Respiratory Tract Sensations" and "Craving Reduction". Scores for each subscale are calculated as the average of its individual item responses of The items are rated on a seven-point scale ranging from 1 (not at all) to 7 (extremely). Higher scores indicate greater intensity of each smoking effect with, for example, greater satisfaction or psychological reward after smoking. Scores will be compared between SREC, TC, and dual use
Time frame: Baseline through study completion, approximately 2 years
Patterns of puffing
Compare the pattern of puffing between SREC and TC use by coding the recorded ad libitum use of SREC vs TC.
Time frame: Baseline through study completion, approximately 2 years
Change in Mean score on the Minnesota Tobacco Withdrawal Scale-Revised (MTWS-R)
The MTWS-R features two separate measures for examining the severity of nicotine withdrawal symptoms in a participant: a self-report scale and an observer scale. The observer scale asks the scale-taker to rate the severity of four symptoms in someone the they know who is experiencing nicotine withdrawal: "angry/irritable/frustrated," "anxious/tense," "depressed," and "restless/impatient." The self-report version asks for rankings of the severity of those same four symptoms, plus eleven others that cannot be observed by outsiders (including such things as "desire or craving to smoke," "insomnia, sleep problems, awakening at night," or "dizziness). Both scales use a Likert-type scale for the severity ratings, ranging from 0 ("not at all") to 4 ("severe"). These scores are tallied to calculate an a total withdrawal discomfort score and will be compared between SREC, TC, and dual use.
Time frame: Baseline through study completion, approximately 2 years
Change in Mean score on the Questionnaire on Smoking Urges (QSU-Brief)
The QSU-Brief consists of 10 statements about the respondent's feelings and thoughts about his or her desire to smoke cigarettes as he or she is completing the questionnaire (i.e., right now). Each response is scored a number ranging from 1 (strongly disagree) to 7 (strongly agree) and total scores are calculated by summing the item scores to compare craving between SREC, TC, and dual use.
Time frame: Baseline through study completion, approximately 2 years
Change in Mean score on the Positive and Negative Affect Scale (PANAS)
The Positive and Negative Affect Schedule (PANAS) is a brief scale is comprised of 20 items, with 10 items measuring positive affect (e.g., excited, inspired) and 10 items measuring negative affect (e.g., upset, afraid). Each item is rated on a five-point Likert Scale, ranging from 1 = Very Slightly or Not at all to 5 = Extremely, to measure the extent to which the affect has been experienced in a specified time frame and the final score is derived out of the sum of the ten items on both the positive and negative side. Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect. The scores will be comparted between SREC, TC, and dual use.
Time frame: Baseline through study completion, approximately 2 years
Changes in mean circadian heart rate
Compare changes in mean circadian heart rate between SREC-only and TC-only use
Time frame: Baseline through study completion, approximately 2 years
Changes in mean blood pressure
Compare changes in blood pressure between SREC-only and TC-only use
Time frame: Baseline through study completion, approximately 2 years
Changes in mean urinary catecholamine
Compare mean urinary catecholamine excretion between SREC-only and TC-only use
Time frame: Baseline through study completion, approximately 2 years
Mean Level of exposure to Tobacco smoke toxicant
Compare levels of exposure of tobacco smoke toxicant between dual SREC-TC use and TC-only use
Time frame: Baseline through study completion, approximately 2 years
Sensitivity of anabasine or nicotelline to nicotine metabolites
Sensitivity is defined as the ratio of anabasine or nicotelline to nicotine metabolites (cotinine or total nicotine equivalents) in urine from SREC-only and TC-only use.
Time frame: Baseline through study completion, approximately 2 years
Specificity of anabasine or nicotelline to nicotine metabolites
Specificity of anabasine or nicotelline will be compared to nicotine metabolites (cotinine or total nicotine equivalents) in urine from SREC-only and TC-only use.
Time frame: Baseline through study completion, approximately 2 years
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Aug 2022 (actual). Primary completion is estimated for Mar 2026, 43 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →